<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02112643</url>
  </required_header>
  <id_info>
    <org_study_id>AAAL9502</org_study_id>
    <nct_id>NCT02112643</nct_id>
  </id_info>
  <brief_title>Selenium in Mild Thyroid Eye Disease in North America</brief_title>
  <acronym>S-ITEDS</acronym>
  <official_title>Selenium - ITEDS: A North American Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Thyroid Eye Disease Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether sodium selenite is helpful in the treatment
      of mild thyroid eye disease in North America.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thyroid eye disease (TED) is a disease in which the soft tissues surrounding the eye can
      become inflamed, scarred, and at times permanently damaged in an autoimmune reaction highly
      associated with abnormal thyroid hormone levels. Some patients have much more severe TED than
      others, but overall, most patients reach a point with relatively stable TED after 1 to 2
      years. A recent European study showed that oral selenium, a trace mineral involved in
      anti-oxidation and immune regulation, could actually alter the course of mild TED, lessening
      its signs and symptoms and even improving the quality of life of those who took it. The
      investigators would like to perform a sister study throughout North America. In this
      randomized, double-blinded, multi-center trial, some subjects with mild TED would be given
      100 micrograms of sodium selenite twice a day; others would receive a placebo. Signs,
      symptoms, and quality of life would be measured at regular intervals throughout the 6 month
      period of drug administration, and for 6 months thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in Quality of Life score</measure>
    <time_frame>Six months</time_frame>
    <description>Using GO-QOL score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in Quality of Life score</measure>
    <time_frame>Twelve months</time_frame>
    <description>GO-QOL score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Thyroid Eye Disease</measure>
    <time_frame>Six months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Thyroid Eye Disease</measure>
    <time_frame>Twelve months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in Clinical Activity Score</measure>
    <time_frame>Six months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Clinical Activity Score</measure>
    <time_frame>Twelve months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Quality of Life score</measure>
    <time_frame>Six months</time_frame>
    <description>TED-PRO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Quality of Life score</measure>
    <time_frame>Twelve months</time_frame>
    <description>TED-PRO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Quality of Life score</measure>
    <time_frame>Six months</time_frame>
    <description>TED-QOL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Quality of Life score</measure>
    <time_frame>Twelve months</time_frame>
    <description>TED-QOL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in development of optic neuropathy</measure>
    <time_frame>Twelve months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Inflammatory Index</measure>
    <time_frame>Six months</time_frame>
    <description>Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Inflammatory Index</measure>
    <time_frame>Twelve months</time_frame>
    <description>Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Inflammatory Index</measure>
    <time_frame>Six months</time_frame>
    <description>Deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Inflammatory Index</measure>
    <time_frame>Twelve months</time_frame>
    <description>Deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in diplopia score</measure>
    <time_frame>Six months</time_frame>
    <description>Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in diplopia score</measure>
    <time_frame>Twelve months</time_frame>
    <description>Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in diplopia score</measure>
    <time_frame>Six months</time_frame>
    <description>Deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in diplopia score</measure>
    <time_frame>Twelve months</time_frame>
    <description>Deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in degrees of restriction</measure>
    <time_frame>Six months</time_frame>
    <description>Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in degrees of restriction</measure>
    <time_frame>Twelve months</time_frame>
    <description>Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in degrees of restriction</measure>
    <time_frame>Six months</time_frame>
    <description>Deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in degrees of restriction</measure>
    <time_frame>Twelve months</time_frame>
    <description>Deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in exophthalmos scores</measure>
    <time_frame>Six months</time_frame>
    <description>Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in exophthalmos scores</measure>
    <time_frame>Twelve months</time_frame>
    <description>Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in exophthalmos scores</measure>
    <time_frame>Six months</time_frame>
    <description>Deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in exophthalmos scores</measure>
    <time_frame>Twelve months</time_frame>
    <description>Deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in eyelid aperture</measure>
    <time_frame>Six months</time_frame>
    <description>Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in eyelid aperture</measure>
    <time_frame>Twelve months</time_frame>
    <description>Improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in eyelid aperture</measure>
    <time_frame>Six months</time_frame>
    <description>Deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in eyelid aperture</measure>
    <time_frame>Twelve months</time_frame>
    <description>Deterioration</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Fasting glucose level</measure>
    <time_frame>Six months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">151</enrollment>
  <condition>Thyroid Associated Ophthalmopathies</condition>
  <arm_group>
    <arm_group_label>Selenium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 micrograms of sodium selenite will be taken orally twice daily (total 200 micrograms daily) for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A placebo pill will be taken orally twice daily for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sodium selenite</intervention_name>
    <description>A 100 microgram pill will be orally administered twice a day for 6 months.</description>
    <arm_group_label>Selenium</arm_group_label>
    <other_name>Selenium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sugar pill</intervention_name>
    <description>The placebo pill will be constructed to look exactly like the selenium pill, but will have no active ingredients. This will be orally administered for 6 months.</description>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older

          -  Able to provide informed consent

          -  Able to swallow pills

          -  Mild thyroid eye disease requiring no past treatment other than ophthalmic drops or
             ointment

          -  Euthyroid: at least 2 months if on medication irregardless of thyroidectomy status; at
             least 6 months after radioiodine therapy; if euthyroid for the year prior to
             enrollment, needs normal thyroid-stimulating hormone (TSH) within last 3 months; if
             uncontrolled for the year prior to enrollment, needs normal TSH and free T4 within
             last 3 months; if TSH low, needs normal T3 and free T4

        Exclusion Criteria:

          -  Moderate or severe thyroid eye disease (based upon International Thyroid Eye Disease
             Society VISA form), including: grade 2 chemosis or lid edema; corneal exposure with
             threat of or resulting in perforation; optic neuropathy; grade 3 restriction of any
             extraocular muscle

          -  Double vision (diplopia) in primary or reading positions

          -  Duration of thyroid eye disease greater than 12 months (as per patient history)

          -  Drug or alcohol abuse

          -  Concurrent or past use of selenium during period of thyroid eye disease

          -  Severe systemic illness (defined by treating physician)

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Micahel Kazim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Thyroid Eye Disease Society</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suzanne Freitag, MD</last_name>
      <phone>617-842-0633</phone>
      <email>suzanne_freitag@meei.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Lefebvre, MD</last_name>
      <phone>617-571-5138</phone>
      <email>daniel_lefebvre@meei.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Yoon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Suzanne Freitag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Lefebvre, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Grace Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francis Sutula, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lora R Dagi Glass, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edward S. Harkness Eye Institute, Columbia University Medical Center, New York-Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Kazim, MD</last_name>
      <phone>212-305-5477</phone>
      <email>mk48@columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kelly Davis, BS</last_name>
      <phone>212-342-1095</phone>
      <email>kd2497@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Kazim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Golnaz Moazami, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bryan Winn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carisa Petris, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Payal Patel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kenneth V. Cahill, M.D.</last_name>
      <phone>614-221-7464</phone>
      <email>kcahill@columbus.rr.com</email>
    </contact>
    <contact_backup>
      <last_name>Jill A. Foster, M.D.</last_name>
      <phone>614-221-7464</phone>
      <email>fosterj@jillfoster.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kenneth V. Cahill, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jill A. Foster, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cameron B. Nabavi, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Craig N. Czyz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Straka, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://thyroideyedisease.org/</url>
    <description>This is the International Thyroid Eye Disease Society (ITEDS) website.</description>
  </link>
  <reference>
    <citation>Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga W; European Group on Graves' Orbitopathy. Selenium and the course of mild Graves' orbitopathy. N Engl J Med. 2011 May 19;364(20):1920-31. doi: 10.1056/NEJMoa1012985.</citation>
    <PMID>21591944</PMID>
  </reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2014</study_first_submitted>
  <study_first_submitted_qc>April 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2014</study_first_posted>
  <last_update_submitted>August 2, 2014</last_update_submitted>
  <last_update_submitted_qc>August 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Michael Kazim</investigator_full_name>
    <investigator_title>Clinical Professor of Ophthalmology and Surgery</investigator_title>
  </responsible_party>
  <keyword>Thyroid eye disease</keyword>
  <keyword>Thyroid orbitopathy</keyword>
  <keyword>Graves' orbitopathy</keyword>
  <keyword>Graves' ophthalmopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Graves Ophthalmopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selenium</mesh_term>
    <mesh_term>Selenious Acid</mesh_term>
    <mesh_term>Sodium Selenite</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

